NovaBridge Biosciences
NBP
$4.26
-$0.01-0.23%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 551.50K | 156.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 551.50K | 156.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 551.50K | 156.00K |
| SG&A Expenses | 3.82M | 7.34M | 11.94M | 14.36M | 7.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.11M | 13.37M | 17.14M | 39.50M | 11.53M |
| Operating Income | -7.11M | -13.37M | -17.14M | -38.95M | -11.37M |
| Income Before Tax | -5.50M | -10.84M | -8.94M | -47.83M | -7.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.50M | -10.84M | -8.94M | -47.83M | -7.74M |
| Earnings from Discontinued Operations | -- | 1.78M | 34.36M | -- | -34.33M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.50M | -9.06M | 25.42M | -47.83M | -42.07M |
| EBIT | -7.11M | -13.37M | -17.14M | -38.95M | -11.37M |
| EBITDA | -7.10M | -13.31M | -17.03M | -38.08M | -10.45M |
| EPS Basic | -0.16 | -0.26 | 0.72 | -1.32 | -1.16 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.07 | -0.28 | -- |
| EPS Diluted | -0.16 | -0.26 | 0.72 | -1.32 | -1.16 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.07 | -0.28 | -- |
| Average Basic Shares Outstanding | 81.70M | 81.50M | 80.93M | 83.29M | 83.19M |
| Average Diluted Shares Outstanding | 35.52M | 35.44M | 35.19M | 36.21M | 36.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |